By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
News for IndiaNews for IndiaNews for India
  • Home
  • Posts
  • Search Page
  • About us
Reading: Dr Lal PathLabs adds genomics heft with SN Genelab deal | Stock Market News
Share
Font ResizerAa
News for IndiaNews for India
Font ResizerAa
  • Economics
  • Business
  • Home
  • Categories
    • Business
    • Economics
  • About us
  • Sitemap
Follow US
  • Advertise
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
News for India > Business > Dr Lal PathLabs adds genomics heft with SN Genelab deal | Stock Market News
Business

Dr Lal PathLabs adds genomics heft with SN Genelab deal | Stock Market News

Last updated: September 28, 2026 2:48 pm
2 months ago
Share
SHARE


Recall that in December 2024, Metropolis had acquired the Delhi-NCR-based Core Diagnostics, a genomics and advanced oncology testing specialist, for ₹247 crore. “Unlike SN Genelab, however, Core Diagnostics was operating only at Ebitda break-even levels at the time of the acquisition,” added Nomura. SN Genelab’s FY26 Ebitda margin stands at 26%. Dr Lal paid about 16 times SN Genelab’s FY26 Ebitda, which seems fair for a fast-growing, high-margin company.



Source link

You Might Also Like

Tata Tech shares jump 10% as company targets $1.3 billion revenue by FY30, bets on aerospace, industrial machinery | Stock Market News

This small-cap stock plunges 42% in 1 year, but Jefferies sees 53% upside – Is a big turnaround coming? Check target | Stock Market News

IREDA shares jump 11% to 4-month high: Is the renewable energy stock finally turning around after 6 months of losses? | Stock Market News

Small-cap stock under ₹50: IT share jumps 8% after collaboration with Mahesh Babu Foundation; do you own? | Stock Market News

Anthropic IPO breaks all records, even SpaceX! What $81.3 billion means for India’s IT and AI stocks? Experts decode | Stock Market News

TAGGED:diagnostic companies acquisitions indiadr lal pathlabs <span class='webrupee'>₹</span>168 crore dealdr lal pathlabs <span class='webrupee'>₹</span>200 crore acquisitiondr lal pathlabs diagnostics businessdr lal pathlabs earnings fy2Dr Lal Pathlabs share pricedr lal pathlabs sn genelab acquisitiondr lal pathlabs stockdr lal pathlabs western india expansionDr. Lal Pathlabsgenomics testing indiaindian diagnostics industrymetropolis core diagnostics acquisitionsn genelab acquisitionsn genelab ebitda marginsn genelab genomics testingsn genelab oncology testingsn genelab rare disease testingsn genelab revenue fy26specialized diagnostics india
Share This Article
Facebook Twitter Email Print
Previous Article Access Denied
Next Article Access Denied

We influence 20 million users and is the number one business and technology news network on the planet.

Find Us on Socials

News for IndiaNews for India
© Wealth Wave Designed by Preet Patel. All Rights Reserved.
  • BUSINESS